Memantine Zentiva Pharma (Memantine Hydrochloride)

Memantine works by blocking the NMDA receptor’s ion channel in a non‑competitive manner. This reduces excessive calcium entry caused by over‑activation of glutamate pathways, limiting excitotoxic neuronal injury that contributes to the cognitive decline seen in Alzheimer’s disease.

The appropriate dose of Memantine Zentiva Pharma is individualized by the prescriber based on the patient’s clinical condition, renal function and tolerability. The prescribing doctor determines the starting dose and any subsequent titration.

The safety of memantine in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, so it should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas most other Alzheimer’s agents are acetylcholinesterase inhibitors (e.g., donepezil). Memantine targets excitotoxic pathways rather than cholinergic deficiency, and it is often used alone or in combination with an acetylcholinesterase inhibitor for complementary effects.

Memantine Zentiva Pharma should be stored at ambient temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight to maintain product stability.

The medication is taken orally, usually once daily with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised.

Serious risks include seizures, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, and emergence of suicidal thoughts or behavior. Patients should be monitored for these events, and any concerning symptoms should prompt immediate medical evaluation.

Memantine is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA antagonists, as these conditions increase the risk of adverse effects.